What cypre.com does

Cypre, Inc. is a privately held biotechnology company headquartered in San Francisco, California that develops and commercializes 3D tumor organoid models for preclinical oncology drug discovery. The company's core platform is built on proprietary VersaGel® hydrogel technology — a tunable extracellular matrix that enables the cultivation of patient-derived tumor cells while preserving oncogenic features — and the trademarked Symphony® platform component used in conjunction with it. The architecture is a three-tiered model integrating a genomically annotated patient-derived tumor core, a stromal layer of human fibroblasts with controlled ECM density, and phenotypic immune readouts incorporating T cells, macrophages, NK cells, and B cells. The platform supports high-content screening across 30+ (and now 42 automated) PDX models spanning lung, colon, pancreatic, renal, melanoma, brain, blood, stomach, and bladder cancers, with multi-omic analytics combining high-content imaging, multiplex cytokine profiling, flow cytometry, and RNA-seq.

Cypre monetizes the platform through two distinct engagement models: (1) Translational Research Services, which delivers project-based, IND-ready preclinical data packages for lead candidate evaluation ahead of IND-enabling studies, with typical 30-60 day turnarounds; and (2) Drug Discovery Partnerships, structured as selective multi-target or multi-year strategic collaborations designed to drive candidates to IND-enabling studies within two years. Pricing is not publicly disclosed and is contract-based on scope and complexity. Go-to-market is enterprise field sales into pharmaceutical and biotechnology customers, supplemented by academic collaborations, with marketing centered on industry conferences (AACR, SITC, BIO Partnering, JPM Healthcare Conference), peer-reviewed publications, webinars (notably with Charles River Laboratories), and thought leadership around NAMs and FDA 2025 animal-testing reduction guidance.

The company was founded by Kolin C. Hribar, PhD (CEO), and operates with a small specialist team spanning biology, operations, engineering, and data. Strategic assets include a core partnership with Charles River Laboratories (formed January 2021) integrating Cypre's organoid platform with CRL's PDX compendium, peer-reviewed validation in the CELLS journal (April 2023), and a scientific advisory board featuring former senior R&D leaders from Nkarta, Eli Lilly, Gilead, Dendreon, Takeda, XOMA, and Abgenix. No institutional venture capital funding rounds have been disclosed.

Name

cypre.com

Legal name

Cypre, Inc.

Website

https://cypre.com

Company type

Private

Operating status

Operating

Short description

Cypre is a San Francisco-based biotech that builds 3D tumor organoid models on proprietary VersaGel® hydrogel technology to deliver preclinical efficacy, mechanism-of-action, and biomarker data for pharmaceutical and biotechnology oncology drug developers.

Ownership category

akta.pro rank

Product category

Preclinical Oncology Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• 3D tumor organoid models
• Tumor microenvironment platform
• Preclinical oncology services
• Hydrogel drug screening
• Immuno-oncology assays

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Translational Research Services: Project-based services for rigorous evaluation of lead candidates at preclinical stage prior to IND-enabling studies. Generates IND-ready data packages for regulatory submissions.
2. Drug Discovery Partnerships: Selective multi-target or multi-year strategic partnerships spanning target identification, lead development and candidate selection. Designed to drive lead candidates to IND-enabling studies within two years.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Cypre provides a proprietary 3D tumor organoid platform built on VersaGel hydrogel technology that recreates the human tumor microenvironment with integrated tumor, stromal, and immune compartments. The company sells Translational Research Services for preclinical evaluation of lead candidates prior to IND-enabling studies, and Drug Discovery Partnerships structured as multi-target or multi-year collaborations spanning target identification, lead development, and candidate selection.

Product overview

Cypre offers a unified 3D tumor organoid platform centered on its proprietary VersaGel® hydrogel technology and Symphony® components. The platform integrates patient-derived tumor cells, stromal fibroblasts, and immune components (T cells, NK cells, macrophages, B cells) within a tunable extracellular matrix to recreate the human tumor microenvironment. Core offerings include the Cypre 3D Tumor Organoid Platform for mechanism of action studies and biomarker discovery, supplemented by Translational Research Services and Drug Discovery Partnerships. The platform supports therapeutic programs from target validation through IND-enabling studies across multiple tumor indications including lung, colon, pancreatic, renal, melanoma, brain, blood, and stomach cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• Cypre 3D Tumor Organoid Platform Proprietary 3D tumor model platform that recreates the tumor-stromal-immune microenvironment to support therapeutic development through IND. Built for mechanism of action studies, biomarker discovery, and predictive preclinical data with integrated tumor, stromal, and immune components. Offered to pharmaceutical and biotechnology sponsors.
• Translational Research Services Rigorous evaluation of lead candidates at the preclinical stage prior to IND-enabling studies. Generates IND-ready data packages to support decision-making and discussions with regulatory agencies. Offered to pharmaceutical and biotechnology sponsors.
• Drug Discovery Partnerships Selective multi-target or multi-year partnership framework spanning target identification, lead development, and candidate selection. Designed to drive lead candidates to IND-enabling studies within two years using Cypre's human-relevant data at each stage. Offered to pharmaceutical and biotechnology sponsors.

Quantifiable outcome

• 30-60 day turnaround for translational data packages
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Charles River LaboratoriescoreStrategic or Co-development Partner · 28 January 2021Cypre and Charles River announced a strategic partnership to leverage Cypre's 3D Tumor Model Platform with Charles River's genomically annotated and extensively characterized PDX Tumor Model Compendium. The partnership enables end-to-end oncology discovery capabilities, combining Cypre's 3D organoid platform with CRL's tumor model collection for in vitro pharmacology and drug screening prior to IND. The collaboration has generated joint publications, conference presentations, and integrated service offerings for cancer drug discovery.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Cellesce: Develops scalable organoid expansion and assay platforms for drug discovery. Comparable as an emerging 3D organoid vendor focused on industrial-scale production of tumor and tissue models for preclinical research.
• DefiniGEN: Provides iPSC-derived cell models and organoid platforms for disease modeling and drug discovery. Comparable to Cypre as a human-relevant in vitro model vendor serving preclinical translational research, particularly in oncology and metabolic disease.
• STEMCELL Technologies: Supplies organoid culture kits, media, and related reagents for 3D in vitro tumor modeling. Comparable to Cypre as an enabling supplier in the same preclinical oncology workflow, with growing overlap in tumor organoid product offerings.

Broad incumbents

• Bio-Techne: Supplies reagents, cytokines, and 3D cell culture tools used in tumor organoid and immuno-oncology workflows. Comparable as an incumbent enabling competitor in the same translational research ecosystem, with overlapping customers in pharma and academic oncology.
• Charles River Laboratories: Global CRO offering a broad portfolio of oncology discovery and safety services, including a PDX Tumor Model Compendium that is co-offered with Cypre's platform. Acts both as Cypre's primary distribution partner and as a broader incumbent competing for the same translational research budgets.
• Thermo Fisher Scientific: Life sciences tools giant offering cell culture, organoid reagents, and preclinical services through its Patheon and PPD CRO arms. Comparable as a broad incumbent that supplies enabling products and competing services across the oncology translational research value chain.

Direct peers

• Crown Bioscience: Provider of patient-derived xenograft (PDX) models and organoid-based preclinical oncology services. Directly comparable to Cypre as a competing translational research platform selling 3D in vitro and in vivo oncology models to the same pharma/biotech customers.
• InSphero: Developer of 3D in vitro microtissue and organoid platforms used for drug discovery and toxicity testing. Directly competes with Cypre's 3D tumor organoid services in oncology and broader preclinical applications.
• Molecular Devices: Supplies 3D cell culture and organoid imaging platforms (e.g., high-content imaging systems) used by pharma and biotech for tumor model screening. Comparable to Cypre in enabling high-content, 3D tumor biology readouts for translational drug discovery.

Others

• Genentech (Roche): Large oncology drug developer and a named past collaborator with Cypre (joint 2019 minisymposium on immune exclusion tumor models). Comparable as a strategic buyer of 3D tumor microenvironment services and a potential anchor customer/partner for translational research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about cypre.com